Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes

To determine how long Gemcitabine and Bevacizumab will stop the cancer from growing in patients with advanced breast cancer.

Inclusion Criteria:

• Must be female and greater than or equal to 18 yrs of age
• Participants must have confirmed cancer with measurable or evaluable, locally recurrent or metastatic disease.
• Participants must have received a taxane as neo-adjuvant and/or adjuvant therapy
• Participants may have received prior hormone therapy for locally recurrent or metastatic disease

Exclusion Criteria:

• Participants with breast cancer overexpressing Human Epidermal growth factor Receptor 2 (HER2) gene amplification
• Prior chemotherapy or targeted therapy for metastatic breast cancer
• Prior treatment with gemcitabine, trastuzumab, lapatinib or bevacizumab in any setting
• History of, or active brain mets
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to treatment, or anticipation of need for major surgical procedure during course of study
• Prior history of high blood pressure crisis
• Have a serious, nonhealing wound, ulcer, or bone fracture